Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117349991 | 11734999 | 1 | I | 20131001 | 20151113 | 20151113 | EXP | HU-PFIZER INC-2013283197 | PFIZER | 63.00 | YR | M | Y | 0.00000 | 20151113 | OT | HU | HU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117349991 | 11734999 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | Oral | 50 MG DAILY, CYCLIC (SCHEME: 2 WEEKS TAKING, 1 WEEK BREAK) | 21938 | 50 | MG | CAPSULE, HARD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117349991 | 11734999 | 1 | Clear cell renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117349991 | 11734999 | HO |
| 117349991 | 11734999 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117349991 | 11734999 | Blood thyroid stimulating hormone increased | |
| 117349991 | 11734999 | Hemiparesis | |
| 117349991 | 11734999 | Renal impairment | |
| 117349991 | 11734999 | Vascular encephalopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117349991 | 11734999 | 1 | 20130131 | 0 |